Home  /  Resource Library  /  Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel treated patients in the TRANSCEND NHL 001 trial

Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel treated patients in the TRANSCEND NHL 001 trial

Study examined healthcare costs associated with cytokine release syndrome and neurological toxicity in patients treated with CAR T therapy lisocabtagene maraleucel.